We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Let's get this back up there
Trinityman......spot on.....
Excellent post. This sums up why I continue to hold this share with confidence, despite currently being in the red. None of the detractors on this board have put together a coherent counter argument against this bullish outlook
Fantastic post. Just giving it another bump back to the top.
Great Post.
Day-traders and de-rampers will also post new posts to keep great POVs / news like this further down the list. I've spotted it a fair few times before. So let's make sure that when Trinity reposts it, it stays near the top for a while. Oh! and the best way to keep deramping idiots (I really don't mind any well informed ones) out of the picture is to NOT reply to them, no matter how tempting it might be, because any reply merely does their work for them, by keeping their post fresh and at the top!
“Drops mic”
Oxford12 - Thanks for that, I'll re-post in the morning.
I fully expect more mis-information and mis-direction throughout December from the day traders and those looking to get in at a much lower price.
ATVB
And yo close down some of the attack on this board lately that we are all sick of.
Trinity man- you always post such sense. Please can you repost this tomorrow morning for all the worriedPI’s?
Yes Meelie, your analogy to penicillin is much more appropriate :-)
mact4... absolutely agree, now I have finally tapped into RM's way of thinking, I agree this drug is a long term game changer, and I will therefore be holding this share very long term.... to the point of getting some sizeable dividends. Hence his huge confidence in this.
Though I would correct your analogy to SNG = Penicillin, rather than paracetamol. In a perfect future personalised diagnostic world, we could one day walk into the doctors surgery with in infection, take a 5 minute test to find out if it's bacterial or viral, then be prescribed either antibiotics or SNG.
Absolutely stonking article, Trinityman. Well written, well argued. Well worth listening to Prof Holgate's interview again. https://hstalks.com/t/4467/update-on-the-sng001-drug-an-inf-therapy-for-covid/?biosci&nocache At 10:58, the interviewer asked: 'This therapy could almost be the beginning of personalised medicine with individuals with viral infections, if they are looking at the genetics of patients?' to which the Prof agreed but suggested that this could be the start of precision medicine. He talks about home treatment - keeping the in the fridge for self-medication. I personally am very excited with the possibilities of this medicine. Just think, SNG could be as ubiquitous as the humble paracetamol.
I have stopped looking at my balance (it's in the red - shrug) but instead my focus is on the SP and chipping in buying this stock at the current highly oversold price. I am holding for a slightly longer term than I had originally intended but the company, product and science is very sound. It is myself that needed to change perspective - and that is only on the the timescale - and not the company.
This is a scientific company run by boffins quite correctly. They have better things to do than answering small shareholders queries.
I notice the detractors on this board have been taking a slightly more subtle approach to their ‘work’ this week. Instead of the usual ‘this will be 50p by Christmas’ posts, we had a small, but persistent cluster of individuals questioning the public relations acumen of the board of directors and their reluctance to hold the hands of investors every step of the way, by spoon feeding them with weekly information.
This has clearly had an unsettling effect on the less experienced investors and created a sense of general unease - exactly what was intended.
The common theme amongst these naysayers is that not one of them has put up a single piece of evidence to suggest that this drug doesn’t work.
Instead there is the growing realisation from healthcare professionals around the world that SNG have made one of the most significant drug discoveries in respiratory medicine since Salbutamol (Ventolin) was discovered way back in 1966.
This novel treatment has been classified as a ‘broad spectrum anti-viral treatment’, so will benefit millions who suffer from the vast majority of lung infections and conditions. This has the potential to empty respiratory wards globally, saving healthcare systems around the world $billions for decades to come.
Commercially, covid has simply accelerated the process, the main driver is the COPD market. This basic fact seems to have escaped the ‘one day experts’ that have crept onto this board over the last seven days.
Commercially and medically, the recurring annual numbers are staggering, take a look:
Chronic obstructive pulmonary disease (COPD) claimed 3 million lives in 2016.
Lower respiratory infections remained the most deadly communicable disease, causing a further 3 million deaths worldwide.
COPD and pneumonia were the 3rd and 4th biggest causes of death globally in 2016, behind heart disease and stroke.
COPD: Annual Deaths:
UK 30,000
Europe 300,000
USA 140,000 = 1 death every 4 minutes
World 3 million (2016)
USA 15 million Americans currently live with COPD symptoms.
Please feel free to copy and paste these figures to use as ammunition from tomorrow and beyond, when replying to posters who attempt to class this as a covid share that has fallen from grace due to vaccine production.
Trust Synairgen’s CEO get on with his job and make good his promise to ‘deliver maximum shareholder value’. The decision by our government not to grant this treatment EUA is morally disgraceful, the company swiftly dealt with this by cleverly teaming up with Clinigen. It is now only a matter of time before a foreign regime decide to grant EUA.
I think the well-used swan analogy is relevant to SNG, in that not much appears to be happening on the surface right now, but underneath there is feverish activity.
Buy, hold and believe in the company, but above all, believe in the science.
https://statistics.blf.org.uk/
https://www.who.int/news-room/fact-sheets/detail/th